Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

International Journal of Impotence Research volume 14, pages 466–471 (2002)Cite this article

Abstract

Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in ‘general’ and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Acici B et al. Apoptosis in the erectile tissue of diabetic and healthy rats Br J Urol 2000; 85: 326–329.

    Article  Google Scholar 

  2. Dahiya R et al. Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction Int Impot Res 1999; 11: (4) 201–206.

    Article  CAS  Google Scholar 

  3. Christ GJ . The penis as a vascular organ: the importance of corporal smooth muscle tone in the control of erection Urol Clin N Am 1995; 22: 727.

    CAS  Google Scholar 

  4. Moreland RB . Is there a role of hypoxemia in penile fiborosis: a view point presented to the society for the Study of Impotence Int J Impot Res 1998; 10: 113–120.

    Article  CAS  Google Scholar 

  5. Cartledge JJ, Eardley I, Morrison JF . Advanced glycation products are responsible for the impairment of corpus cavernosal smooth muscle relaxation in diabetes Br J Urol 2001; 87: (4) 402–407.

    Article  CAS  Google Scholar 

  6. Sáenz de Tejada I et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence New Engl J Med 1989; 320: 1025–1030.

    Article  Google Scholar 

  7. West IC . Radicals and oxidative stress in diabetes Diabet Med 2000; 17: 171–180.

    Article  CAS  Google Scholar 

  8. Katzenstein L . Viagra—the remarkable story of the discovery and launch CMD Publishing: New York 2001.

  9. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  Google Scholar 

  10. Padma-Nathan H et al. On-demand IC351 (CialisTM) enhances erectile function in patients with erectile dysfunction Int J Impot Res 2001; 13: 2–9.

    Article  CAS  Google Scholar 

  11. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at home clinical trial Int J Impot Res 2001; 13: 192–199.

    Article  CAS  Google Scholar 

  12. Rendell M, Rajfer J, Wicker P, Smith M . Sildenafil for treatment of erectile dysfunction in men with diabetes JAMA 1999; 281: 421–426.

    Article  CAS  Google Scholar 

  13. Sáenz de Tejada I, Emmick J, Anglin G, Fredlund P . Tadalafil (IC351) taken as needed by diabetic men with erectile dysfunction Int J Impot Res 2001; 13: S65.

    Article  Google Scholar 

  14. Goldstein I et al. Vardenafil improved erectile function in diabetic men with erectile dysfunction Int J Impot Res 2001; 13: S65.

    Google Scholar 

  15. Goldstein I et al. Vardenafil, a new selective PDE5 inhibitor, significantly improved all IIEF domains and showed a favorable safety profile in patients with impaired erectile function and diabetes mellitus Int J Impot Res 2001; 13: S64.

    Google Scholar 

  16. Padma-Nathan H et al. CialisTM (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED) J Urol 2001 (Suppl) 165: 224.

    Google Scholar 

  17. Mazzu A, Nicholls A, Zinny M . Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects Int J Impot Res 2001; 13: S64.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Togus VA Medical Center, Togus, Maine, USA

    M A Vickers & R Satyanarayana

  2. Department of Surgery, Division of Urology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

    M A Vickers

Authors
  1. M A Vickers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Satyanarayana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Vickers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vickers, M., Satyanarayana, R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 14, 466–471 (2002). https://doi.org/10.1038/sj.ijir.3900910

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900910

Keywords

This article is cited by

Search

Advanced search

Quick links